How to Treat Polymyelgeromatica

The suppression of the SEDRAID and CRP to me is a big negative of TOSLISMAB and GCA. So are we treating the inflammatory manifestations but not vasculopathy? And it's something we really have to think about. We don't know how long to treat these patients for.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app